1. Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor

   • Marian Iwamoto
   • Evan J. Friedman
   • John A. Wagner

   Review Article 03 July 2013 Pages: 493 - 508

   

2. Compatibility of intravenous fosaprepitant with intravenous 5-HT₃ antagonists and corticosteroids

   • Susan Sun
   • Joseph Schaller
   • Brett Duersch

   Original Article 17 July 2013 Pages: 509 - 513

3. Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel

   • D. Sémiond
   • S. S. Sidhu
   • P. Vrignaud

   Original Article 03 July 2013 Pages: 515 - 528

   

4. Clinical effects of A4889G and T6235C polymorphisms in cytochrome P-450 CYP1A1 for breast cancer patients treated with tamoxifen: implications for tumor aggressiveness and patient survival

   • Cassio Cardoso-Filho
   • Luis Otavio Sarian
   • Maria Salete Costa Gurgel

   Original Article 11 July 2013 Pages: 529 - 535

   

5. A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer

   • Dana E. Rathkopf
   • Joel Picus
   • George Wilding

   Original Article 03 July 2013 Pages: 537 - 544

   

6. A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer

   • Krishna Rao
   • Sini Kalapurakal
   • K. Thomas Robbins

   Original Article 25 July 2013 Pages: 545 - 552

   

7. Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells

   • Salaheldin S. Hamed
   • Robert M. Straubinger
   • William J. Jusko

   Original Article 09 July 2013 Pages: 553 - 563

   

8. Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study

   • Changhoon Yoo
   • Mi Ra Yun
   • Sung-Bae Kim

   Original Article 11 July 2013 Pages: 565 - 575

   

9. Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors

   • Kazunori Honda
   • Noboru Yamamoto
   • Tomohide Tamura

   Original Article 17 July 2013 Pages: 577 - 584

   

10. Scheduling of paclitaxel and gefitinib to inhibit repopulation for optimal treatment of human cancer cells and xenografts that overexpress the epidermal growth factor receptor

    • Andrea S. Fung
    • Man Yu
    • Ian F. Tannock

    Original Article 14 July 2013 Pages: 585 - 595

    

11. The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor

    • Michele Visentin
    • Ersin Selcuk Unal
    • I. David Goldman

    Original Article 24 July 2013 Pages: 597 - 606

    

12. A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients

    • Meagan J. Bemer
    • Mohamed Sorror
    • Jeannine S. McCune

    Original Article 02 August 2013 Pages: 607 - 618

    

13. Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours

    • Takashi Seto
    • Taito Esaki
    • Xiaojin Shi

    Original Article 28 July 2013 Pages: 619 - 627

    

14. CPT-11 as a second-line treatment for patients with advanced/metastatic gastric cancer who failed S-1 (CCOG0702)

    • Yoshinari Mochizuki
    • Norifumi Ohashi
    • Yasuhiro Kodera

    Original Article 24 July 2013 Pages: 629 - 635

    

15. A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer

    • Yee Chao
    • Chen-Yi Wu
    • Chung-Pin Li

    Original Article 03 August 2013 Pages: 637 - 642

    

16. Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer

    • Toshihiko Doi
    • Kei Muro
    • Atsushi Ohtsu

    Original Article Open access 07 August 2013 Pages: 643 - 652

    

17. Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer

    • Taejong Song
    • Min Kyu Kim
    • Duk Soo Bae

    Original Article 03 August 2013 Pages: 653 - 660

    

18. Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes

    • Jill M. Kolesar
    • Anne M. Traynor
    • William R. Schelman

    Original Article 01 August 2013 Pages: 661 - 667

    

19. The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer

    • Beatrice Mohelnikova-Duchonova
    • Veronika Brynychova
    • Pavel Soucek

    Original Article 11 August 2013 Pages: 669 - 682

    

20. Molecular and cytogenetic changes in multi-drug resistant cancer cells and their influence on new compounds testing

    • Ana Podolski-Renić
    • Milka Jadranin
    • Milica Pešić

    Original Article 10 August 2013 Pages: 683 - 697

    

21. Effects of β-lapachone, a new anticancer candidate, on cytochrome P450-mediated drug metabolism

    • In Sook Kim
    • Yun Kim
    • Hye Hyun Yoo

    Short Communication 23 July 2013 Pages: 699 - 702

22. The small-molecule TNF-α inhibitor, UTL-5g, delays deaths and increases survival rates for mice treated with high doses of cisplatin

    • Jiajiu Shaw
    • Joseph Media
    • Fredrick Valeriote

    Short Communication 24 July 2013 Pages: 703 - 707

    

23. Short communication: bendamustine-related hemolytic anemia in chronic lymphocytic leukemia

    • Neta Goldschmidt
    • Alexander Gural
    • Moshe E. Gatt

    Short Communication 02 August 2013 Pages: 709 - 713